Ann: Trading Halt, page-9

Thanks Deano, as the CTR site isnt always up to date, i suggest you , and other, look back at the 5th of April announcment. outline in detail the trial, the outcomes to date,

Study Outcomes to date (at 5 April)
 Demonstrated safety and tolerability across the dosing regimen.
 No Serious Adverse Events (SAEs) reported.
 Patients are showing positive trends and improvements compared to their baseline assessments
measured at the commencement of the trial.
 Improvements were observed with trial patients in key behavioural indicators related to irritability,
social interaction, mood and communication.
 The improvements were unique to each trial participant given the complexities of how ASD affects
children.

Assessments of efficacy:
Efficacy will be monitored and measured through parent/carer and physician questionnaires.
The secondary outcomes measures listed below will be used to assess potential improvements of:
 Irritability
 Hyperactivity
 Mood
 Self-stimulation
 Sleep disorders
 Seizures
 Behavioural Crises
 Social Interaction
 Communication

there is then detail on how these secondary endpoint were assessed (i.e. the relevant measurment scale that is used in the industry)... It is worth a read..

I agree completely on understanding why the results have taken so long, so many data points, and they did note that each trial participant had different results. So that take a lot of time to work through and comprehend.